Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma
Published on 18 December 2025
Dr Tycell Phillips discusses the phase 2 GLOVe trial, combining the CD20/CD3 bispecific antibody glofitamab with venetoclax and lenalidomide for first-line high-risk mantle cell lymphoma (MCL).
He highlights a 100% complete response rate and 95% undetectable minimal residual disease (uMRD) after short follow-up, with manageable cytokine release syndrome (CRS) and no disease progression observed in the study cohort.